Kiniksa Pharmaceuticals Ltd (KNSA NASDAQ) stock market data APIs
$73.6119
0.48(0.7%)
as of August 3, 2026
Try our APIs with
free plan!
Kiniksa Pharmaceuticals Ltd Financial Data Overview
Price chart is built with
Anychart
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prev. Close
73.6119
Open
74.0919
High
75.397
Low
72.0558
52 wk Range
31.78-82.94
Market Cap
5 728 M
P/E Ratio
74.1515
Shares Outstanding
48 289 K
Revenue
841 M
EPS
0.3
Beta
0.085
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kiniksa Pharmaceuticals Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kiniksa Pharmaceuticals Ltd data using free add-ons & libraries
Get Kiniksa Pharmaceuticals Ltd Fundamental Data
Kiniksa Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue: 841 M
- EBITDA: 102 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Kiniksa Pharmaceuticals Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-07-28
- EPS/Forecast: 0.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kiniksa Pharmaceuticals Ltd News
New
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
Kiniksa Pharmaceuticals International, plc KNSA used its second-quarter 2026 earnings call to emphasize accelerating ARCALYST adoption and a higher full-year sales outlook. Management also moved KPL-3...
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
Madrigal Pharmaceuticals MDGL reported second-quarter 2026 loss of $1.99 per share, narrower than the Zacks Consensus Estimate of a loss of $2.55. In the same quarter last year, the company had incurr...
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
Teva Pharmaceutical Industries Limited TEVA reported second-quarter 2026 adjusted earnings of 2 cents per share, which missed the Zacks Consensus Estimate of 8 cents. Adjusted earnings declined 97% y...
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Kiniksa Pharmaceuticals International, plc (KNSA) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the mom...
Get Kiniksa Pharmaceuticals Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
